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Case Report
Severe nitrofurantoin lung disease resolving without the Severe nitrofurantoin lung disease resolving without the Severe nitrofurantoin lung disease resolving without the Severe nitrofurantoin lung disease resolving without the Severe nitrofurantoin lung disease resolving without the use of steroids use of steroids use of steroids use of steroids use of steroids itrofurantoin is an antimicrobial drug that is most nitrofurantoin, 100 mg, every other day for the past three years. commonly used as a prophylactic agent against urinary Her other regular medications were omeprazole 20 mg and tract infections (UTIs) (long and short-term) and for the aspirin 81 mg both given daily. treatment of acute or recurrent cystitis. Pulmonary toxicity is a potentially serious and even fatal adverse drug reaction of Physical exam revealed a well developed, well nourished female nitrofurantoin treatment [1] [2] [3] [4] [5] and although it occurs in mild respiratory distress at rest. Her vital signs were stable infrequently, nitrofurantoin is one of the most common and room air oxygen saturation was 93%. Examination of the medications associated with lung injury. 
N

Case History
A 71-year-old female presented with symptoms of dyspnea on exertion and productive cough with clear sputum that had intensified over the past three years. At the time of the initial visit, she had difficulties with activities of daily living, such as going to the bathroom independently and cooking for herself. She was known to have gastroesophageal reflux disease and stable Barrett's esophagitis. The patient also had a distant history of an untreated positive tuberculin skin test.
She was a retired nurse with no known occupational exposures, previous lung disease and no significant smoking history. She had one dog at home and no other pets. Her only other significant medical problem was chronic urinary tract infections and she had been placed on suppressive therapy with examination was unremarkable. A chest radiograph [ Figure 1 ] and computerized tomographic scan of the chest [ Figure 2 ] obtained approximately one week before the examination revealed patchy airspace disease and prominent calcified hilar lymphadenopathy. A recent cardiac catheterization performed because of suspicion of heart failure, showed no evidence of coronary artery disease and normal heart function.
An adverse drug reaction to nitrofurantoin was considered and the drug was stopped. However, other conditions were also considered and a bronchoscopy with multiple transbronchial lung biopsies was performed the following week. Pathological evaluation of the biopsy specimens showed organizing pneumonia [ Figure 3 ]. No granulomas, vasculitis or viral changes were appreciated. A Gomori methenamine silver stain was negative for fungal organisms. Pulmonary the patient was warned to not restart the medication. Due to her advanced age and history of untreated positive tuberculin skin test, the decision was made to withhold corticosteroid therapy and monitor her clinically. She felt some subjective improvement within one week and after several months, her function tests were performed three weeks after stopping nitrofurantoin [see inset in Figure 3 ] and revealed a restrictive pattern of lung function (forced vital capacity (FVC) diminished to 57% predicted, total lung capacity (TLC) of 70% predicted) with a carbon monoxide diffusing capacity (DLCO) of 28% of predicted.
The pathologic findings, clinical course and long-time treatment with nitrofurantoin were most consistent with a chronic adverse drug reaction (ADR) to nitrofurantoin and symptoms markedly improved and the airspace infiltrates seen on her chest radiographs began to clear [ Figure 5 ]. Pulmonary function tests showed normalization of her FVC (rising to over 90% predicted) within five months and more gradual but progressive improvement in her DL,co [ Figure 4 ]. She was able to resume her usual activities without cough or dyspnea.
Discussion
In two large Swedish surveys, Holmberg et al found that most patients who develop pulmonary reactions to nitrofurantoin are women with a median age of 60 to 70 years of age. ) .
thought to be due to a hypersensitivity reaction from the drug. Symptoms that develop after six months of therapy are generally considered to be chronic manifestation of the disease and have been thought to be the result of toxicity rather than hypersensitivity. However, over the past 30 years, there have been case reports that suggest that other types of pulmonary reactions can be caused by exposure to nitrofurantoin. These include pulmonary fibrosis [9] [10] [11] [12] and bronchiolitis obliterans organizing pneumonia. [13, 14] While the timing and mechanisms of injury are varied, the treatment of chronic pulmonary injury from nitrofurantoin is usually the same: cessation of the drug combined with corticosteroid nitrofurantoin develops respiratory symptoms and lung infiltrates. that the older classification of nitrofurantoin lung as either acute or chronic, with the latter frequently irreversible, is incomplete and corticosteroids may be less necessary than previously thought. Nevertheless, it remains very important to suspect a drug reaction whenever a patient taking 
